Table 3 The most common treatment-emergent adverse events with an incidence of 2% or greater
From: Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
Treatment-emergent adverse event | Incidence, n (%) |
|---|---|
Dizziness | 7 (6.0) |
Tremor | 7 (6.0) |
Dyskinesia | 6 (5.2) |
Bradykinesia | 4 (3.4) |
Somnolence | 4 (3.4) |
Muscle Rigidity | 5 (4.3) |
Asthenia | 6 (5.2) |
Dry mouth | 4 (3.4) |
Application and Instillation Site Reactions*/Application site pruritis | 3 (2.6) |